Pharma & Healthcare

About IB Banking & Financial Services Consumer & Retail Industrials Infrastructure, Real Assets & Conglomerates New Age Technology Pharma & Healthcare Telecom, Media & Enterprise technology

Pharma & Healthcare

Strong demand outlook in domestic and global markets posits India’s Pharma and Healthcare Industry at an inflection point. Axis Capital is able to contribute strongly to corporate value creation as the segment gets a fillip from growth in innovation, realignment in global supply chains and favourable regulatory support.

Segments

Hospitals
Pharma Value Chain (Intermediates, API, Formulations)
Biopharmaceuticals (Biologics, Biosimilars)
Outsourcing (CRO, CDMO, CMO)

Transactions

Rubicon research

₹ 13,775 Mn

IPO Oct 2025
Alkem lab

₹ 8,827 Mn

Block Jun 2025
Alkem labs

₹ 4,870 Mn

Block Aug 2024
Akums drugs &
pharmaceuticals ltd.

₹ 18,567 Mn

IPO Jul 2024
Emcure pharmaceuticals
ltd.

₹ 19,520 Mn

IPO Jul 2024
Alkem labs

₹ 9,900 Mn

Block Jun 2024
Alkem labs

₹ 4,460 Mn

Block Aug 2023
Mankind pharma ltd.

₹ 43,264 Mn

IPO Apr 2023
Supriya lifesciences ltd

₹ 7,000 Mn

IPO Dec 2021
Medplus health services
ltd

₹ 13,980 Mn

IPO Dec 2021

Krishna institute of
medical science ltd

₹ 21,440 Mn

IPO Jun 2021
Laxmi organic industries

₹ 6,000 Mn

IPO Mar 2021

Axis Capital’s pharma & healthcare practice is led by

Ujjwal Singh Managing Director
Ujjwal leads pharma and healthcare coverage for Axis Capital. He has 19 years of experience in investment banking across M&A, debt, capital markets and private equity financing. He has previously worked with organizations like Avendus, JM Financial, Motilal Oswal and Citibank. Ujjwal has an MBA degr...

Show More Reach Ujjwal Singh

;

How can we help you?

Reach out to discover how India’s leading investment bank can help you reach your financial and strategic goals.

Connect with us

;

Our Location

Research Login